Biocept Inc. (NASDAQ: BIOC) Q2 2020 earnings call dated Aug. 12, 2020 Corporate Participants: Jody Cain -- Investor Relations Michael W. Nall -- President and Chief
Biocept (NASDAQ: BIOC) reported a narrower loss in the second quarter of 2020. The company's revenue declined by 23% year-over-year to $917,000,
Investing in microcap stocks are considered to be risky; even higher so in uncertain market environments like the one we are seeing
Biocept Inc. (BIOC) Q1 2020 earnings call dated May 13, 2020 Corporate Participants: Jody Cain -- Investor Relations Michael W. Nall -- President and Chief Executive
Biocept, Inc. (NASDAQ: BIOC) reported a narrower loss in the fourth quarter of 2019 driven by higher revenue. The bottom line was
Biocept (NASDAQ: BIOC), a leading molecular oncology diagnostics company, reported a net loss for the second quarter. Revenues increased sharply and topped
Biocept (BIOC) narrowed its loss in the fourth quarter, beating analyst estimates. However, sales failed to impress the street. Shares of the
Biocept (BIOC) is scheduled to report fourth quarter and full year 2018 results on March 28, Thursday, after the regular trading hours.